ReviewTherapeutics and clinical risk management2019

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients.

Shi Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.